# A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis

> **NCT05447260** · PHASE4 · UNKNOWN · sponsor: **Qilu Hospital of Shandong University** · enrollment: 87 (estimated)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT05447260
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-10
- **Primary completion:** 2022-12-10
- **Final completion:** 2023-12-10
- **Target enrollment:** 87 (ESTIMATED)
- **Last updated:** 2022-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05447260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05447260, "A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05447260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*